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Abstract
Giant cell arteritis (GCA) is a vascular condition characterized by ocular, systemic and neurological symptoms. Visual
loss is the dreaded complication of this condition, prompting expedient diagnosis and treatment. Treatment typically
involves prolonged glucocorticoid therapy which is often accompanied by several undesired side effects. In this report,
we document one patient’s experience with GCA, its treatment, and relapse. Particularly, the patient highlights the
difficulties and successes he had with the disease and its treatment. We also document the physician perspective on this
disease and its treatment, specifically discussing the significance of prolonged treatment with glucocorticoids. We
comment on the importance of patient experience and engagement in the setting of GCA and its management,
particularly focusing on our recommendations of patient education over multiple visits and individualizing
glucocorticoid treatment.
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Introduction
Giant cell arteritis (GCA) is a chronic inflammatory
condition of medium to large sized arteries primarily
located in the head, neck, and arms. The expected survival
from diagnosis is under four years with the incidence of
GCA peaking at the age of 70 and rarely being seen in
individuals under 50.1,2 With sufficient clinical suspicion,
oral or intravenous (IV) glucocorticoid treatment should
be promptly started, and a temporal artery biopsy is
required to confirm the diagnosis.1
Given the long duration of treatment and the
complications associated with prolonged glucocorticoid
therapy, active patient involvement is crucial. While an
extended glucocorticoid tapering regimen can lower
relapse risk, prolonged use of glucocorticoids can cause
several side effects including suppression of the
hypothalamus-pituitary-adrenal axis.3 In this paper, we
hope to highlight the importance of active patient
engagement in individualizing glucocorticoid therapy.
Active patient engagement involves collaboration between
patients, their friends and family, and health care
professionals involved in their care.4 We invited SR, a
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patient with a protracted course of GCA, to share his
experience and perspectives to highlight the importance of
patient engagement in the management of GCA.
Combined with the physician perspective we discuss the
key areas of importance for patient engagement in the
management of GCA.

General Narrative
SR’s Journey with GCA

I had no major health issues until May 2012. Then, I
started having a non-stop cough, severe headaches, pain in
the jaw, neck, as well as a fever and sweats. My scalp was
very sensitive to touch, and I had to put a pillow under my
neck instead of my head. I had extreme fatigue and had
great difficulty in standing or walking which led to me
needing to lie down most of the time. My right eye would
go completely blind, but the sight would return after a
couple minutes.
Not realizing what was happening, when I travelled
overseas to take care of my ailing father, I saw a doctor.
He prescribed me capsule-type inhalers, cough syrup and
gave some injections. I was feeling very weak and in three
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days my right eye went blind twice for a couple of minutes.
Meanwhile my headaches and chills were unbearable.
Simultaneously, I had an attack of arthritis and all my
joints felt frozen. Ultimately, I decided to cut short my six
weeks’ vacation to just one week and returned to Canada
in a wheelchair. When I returned, I saw my family doctor.
He had x-rays taken of my chest, which were normal, and
he prescribed inhalers which did not work. Cough syrup
was effective only for an hour or two.
I did not think my symptoms were severe enough to
warrant a hospital visit and was worried I would be
wasting hospital resources for just a common headache
and cough. At the same time, I felt very desperate and
helpless with nothing to look forward to the next morning.
Out of this desperation, I remembered I booked an
appointment with the ophthalmologist who completed my
cataract surgery. After looking at my eye, he sent me to the
emergency room as, I was having “mini strokes.” Three
months later from my initial symptoms, I was seen by Dr.
ANES. He looked at my eyes, sent me for bloodwork, and
told me I have vasculitis, a condition requiring high-dose
steroids, which he started, and he arranged for a temporal
artery biopsy. A few days later I had the biopsy where they
took a piece of the artery from my head. I was 69 years old
when the result came back positive confirming the
diagnosis of GCA/vasculitis.
Within 24 hours of taking prednisone, all my symptoms
seemed to have disappeared. I was full of energy again and
felt like going and digging my garden. However, over time,
I realized my GCA symptoms did not disappear
completely even with the steroids, and Dr. ANES warned
me of the possible side effects I might experience. He
would also ask me about these side effects at each
appointment, and over time I started to notice these side
effects with prednisone. I was tossing and turning all night
desperately trying to sleep, sleeping no more than 4 hours
per night. I could not stop eating, and my waistline
increased from 31 to 34 inches while my face became
round and puffy. After being a previous runner, I could
not walk more than 400m. My social life suffered
tremendously. I could neither make nor receive phone
calls, simply because my hands were trembling, unable to
support the weight of the receiver. This had a tremendous
toll on me, both emotionally and psychologically. I felt I
was totally useless. Also, after never having difficulties
with my sugars, they went beyond the range of my
glucometer. My wife rushed me to the hospital where they
put me on insulin infusion. According to the doctors, I
also had mild cognitive impairment. The doctor said it
could be due to my vasculitis, arthritis, or both. I discussed
the impact of the side effects of the steroid treatment on
my life with my family and Dr. ANES. He made
suggestions for how to cope with some of the side effects
which helped me. For example, he suggested trying
melatonin for my sleeping difficulties and a medication to
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help with my nausea and reflux. However, after multiple
years of living with these side effects and mostly resolved
GCA symptoms, we ultimately decided to taper my
prednisone, eventually discontinuing it. I did well without
the prednisone and noticed a marked improvement in my
overall quality of life. I was very thankful of Dr. ANES’s
understanding of the impact the prednisone was having on
my quality of life. However, 5 years after discontinuing
prednisone I had sharp burning pain and severe shaking in
my right thigh, prompting my wife to take me to hospital.
With a negative CT head, I was sent home; however, I felt
my original symptoms of GCA had returned in a milder
form.
Dr. ANES checked my inflammatory markers, and I was
ultimately treated with IV steroids for three days, followed
by 60mg oral prednisone for relapse of GCA. As can be
imagined, this came as deeply disappointing and upsetting
news. But this time I knew how to better take care of the
side effects. With my family’s support, and vigilantly
looking for and treating side effects, I slept 6-7 hours, did
not feel as hungry, and didn’t have any changes to my
body. I had enough energy to do the things around the
house and work in my garden. Psychologically and
emotionally, I am much better now than I was during the
initial attack. The only issue I have at present is that my
walk is very unsteady, and I cannot walk for more than ten
minutes. In my current prednisone taper schedule, I
should be finished in the coming months. I am sharing
this personal information so that anyone else who may be
unfortunate to get GCA may benefit from my experience
and understand the importance of speaking with their
family and physician to tailor their glucocorticoid therapy
to best suit their needs and ensure that side effects are
treated when possible.

Physician Perspective

Mr. SR’s clinical presentation is typical for GCA. Highdose steroid therapy should not be withheld while awaiting
temporal artery biopsy, as there is a risk for visual loss and
other vasculitic complications of GCA if treatment is not
initiated immediately. Patients must be well-educated
about the condition, the potential complications, treatment
with corticosteroids and the potential side effects, and the
need for serial inflammatory markers.
The British Society of Rheumatology provides guidelines
for starting dosages as well as taper of steroids in GCA,
however, there is no standard protocol.5,6 Given the longterm steroid therapy, patients should be advised to be
closely followed to screen for systemic side effects.
Common side effects of high-dose corticosteroids include
gastric irritation that may result in gastric ulcer and
gastrointestinal bleeding, steroid induced hyperglycemia
hypertension, insomnia, mood changes, increased appetite,
weight gain, cushingoid features, osteoporosis, and
ecchymosis. Patients with preexisting conditions such as
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diabetes and hypertension must have their blood glucose
and blood pressure closely monitored. Gastrointestinal
prophylaxis is required, especially if there is a previous
history of peptic ulcer disease. Bone density should be
monitored and calcium and vitamin D supplements in
appropriate cases. Routine ocular screen for steroidinduced complications including glaucoma and cataract is
also essential.
With the multitude of steroid-induced adverse effects,
patient education will not be complete in just one
encounter. Apart from advising the patient to be vigilant
to monitor for recurrence of GCA symptoms, it is also
crucial for the patients to also watch for the adverse
effects of steroids, in order to manage it promptly. It is
very important to inform the patient of the possible side
effects prior to beginning steroid therapy to obtain
informed consent. In my opinion, verbal screening for
steroid induced complications should be performed at
each patient encounter as well. By implementing these
principles, I was able to better understand the impact of
the steroid therapy on SR’s life, particularly when his
quality of life was suffering greatly. Understandably, this is
an overwhelming situation from the patient’s perspective,
as steroids are often considered double-edged sword – the
significant benefit of saving vision and other complications
of GCA and at the same time to deal with the side effects
from the protracted use of prednisone. Patient’s insight to
the serious vision- and life-threatening diagnosis, and the
understanding of the potential side effects of steroids will
help the patient to combat the difficulties that may arise
after starting the steroid therapy. I encouraged SR to bring
family members to his appointments such that they could
also be educated on GCA, its treatment, possible side
effects, and how best to manage these. I also recognized
the strong family support he received and wanted to
encourage his reliance on a strong support system. Friends
and family play a key role in providing consistent social
and emotional support as well as assisting with other
factors such as medication adherence.7 Physicians should
consider the importance of these social factors and
encourage patients to actively involve their family and
friends in their health where they deem applicable.
Screening for steroid induced complications also requires
teamwork, with family physicians, optometrists, and/or
ophthalmologists needing to be closely involved in patient
care to monitor systemic and ocular side effects of longterm prednisone therapy. If SR’s side effects were to
become too severe, methotrexate in combination with
corticosteroids has been studied as initial treatment of
GCA patients as well as in patients with GCA relapse.8–10
Tocilizumab, a biological agent has been found to effective
in GCA patient in two studies, and it has been approved
by the US and European regulatory authorities in the
management of GCA.11,12
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Reflections and Recommendations
SR’s presentation to ophthalmology was consistent with
typical GCA symptoms and risk factors. His experience
with GCA relapse and prolonged prednisone treatment
highlight the importance of active patient engagement in
this disease. We hope to have highlighted the importance
of communication with the patient about the side effects
of glucocorticoid treatment at each physician-patient
encounter and the importance of individualizing
glucocorticoid treatment based on the impact on the
patient’s quality of life.
Extended treatment with prednisone, the recommended
treatment for GCA, can come with a series of
complications.13,14 Despite an immediate short-term gain
in energy and functionality following prednisone initiation,
over time, SR’s sleep quality, glucose and weight
regulation, strength, and social situation greatly
deteriorated. Long term treatment with glucocorticoids for
GCA can lead to the development of obesity, diabetes
mellitus, gonadal dysfunction, hypertension, fluid retention
and pedal edema, weakness, and osteoporosis.13,15 The
significant impact these side effects can have on a patient’s
quality of life are an important factor to consider when
planning appropriate management. For example, weight
loss is an effective treatment for diabetes and reduces
some of the risks associated with obesity, however, would
be very difficult for a patient who is also dealing with
fatigue and weakness.16 Thus, it is especially important to
actively engage patients to determine which aspects of
their diagnosis or complications caused by treatment cause
the largest impact to their quality of life. Incorporating
questions about quality of life and asking patients about
what symptoms, GCA-related or prednisone-related, into
the routine GCA patient interviews can be very beneficial
in individualizing steroid therapy for the patient. Providing
support and resources to assist with lifestyle modifications
is also crucial. For example, sleep quality can be impacted
by many factors, some of which are modifiable, such as
the use of melatonin. Gastrointestinal prophylaxis is
similarly important. Furthermore, tocilizumab and
methotrexate may be viable alternative treatments for
patients who experience significant complications because
of long-term glucocorticoid treatment that severely reduce
their quality of life.17,18
Involving patients in the management of their health has
been shown to improve outcomes and be a key
component of effective healthcare.19,20 As evidenced by
SR’s story, GCA can cause significant changes to a
patient’s quality of life, with symptoms lasting for an
extended period despite long-term treatment, potential to
relapse even after treatment and recovery, and additional
symptoms caused as a side effect of prolonged
glucocorticoid treatment. The fear and anxiety of possibly
having a relapse can contribute to the psychological impact
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of a GCA diagnosis.21 GCA relapses are not uncommon,
with some estimates ranging from 43% to 80% of GCA
patients experiencing a relapse.22 By understanding the
significance of a relapse and the difficulties that come as a
result of the diagnosis, physicians can involve the patient
to better tailor management strategies to address these
concerns.

6.

7.
In modern times, increased importance has been placed on
the role of the patient perspective in the management of
chronic disease. Recently, a disease specific patientreported outcome measure has been developed to better
understand a patient’s experience with GCA and may play
an important role in future clinical trials and eventually
clinical practice.23 It is important to highlight that any
individual’s journey with GCA or a prolonged
glucocorticoid treatment is unique, and management
should reflect this fact. Interestingly, patients who are
actively engaged in the management of their chronic
condition often lead their healthcare team to deliver more
responsive care.24
In conclusion, the perspectives shared by SR and ANES
demonstrate the crucial role of patient engagement in
ensuring optimal clinical outcomes. Particularly, we have
highlighted the importance of patient education about the
side effects of prolonged glucocorticoid therapy and
recommend verbal screening for side effects at every
patient encounter. Furthermore, we stress the importance
of individualizing glucocorticoid therapy in patients who
may be experiencing a serious impact on their quality of
life while on prednisone.
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